throbber
Immunoassays for the quantification of ALK and
`phosphorylated ALK support the evaluation of on-target
`ALK inhibitors in neuroblastoma
`Elizabeth R. Tucker1†, Jennifer R. Tall1,2†, Laura S. Danielson1, Sharon Gowan3, Yann Jamin4,
`Simon P. Robinson4, Udai Banerji2 and Louis Chesler1
`
`1 Paediatric Solid Tumour Biology and Therapeutics Team, Division of Clinical Studies and Cancer Therapeutics Division, The Institute of
`Cancer Research, Sutton, Surrey, UK
`2 Clinical Pharmacodynamic Biomarker Team, Cancer Therapeutics Division, The Institute of Cancer Research, Sutton, Surrey, UK
`3 Tumour Biology and Metastasis, Cancer Therapeutics Division, The Institute of Cancer Research, Sutton, Surrey, UK
`4 Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton, Surrey, UK
`
`Targeted inhibition of anaplastic lymphoma kinase (ALK) is a successful
`approach for the treatment of many ALK-aberrant malignancies; however,
`the presence of resistant mutations necessitates both the development of
`more potent compounds and pharmacodynamic methods with which to
`determine their efficacy. We describe immunoassays designed to quantitate
`phosphorylation of ALK, and their use in preclinical models of neuroblas-
`toma, a pediatric malignancy in which gain-of-function ALK mutations
`predict a poor overall outcome to conventional treatment. Validation of
`the immunoassays is presented using a panel of neuroblastoma cell lines
`and evidence of on-target ALK inhibition provided by treatment of a
`genetically engineered murine model of neuroblastoma with two clinical
`ALK inhibitors, crizotinib and ceritinib, highlighting the superior efficacy
`of ceritinib.
`
`Keywords
`ALK; neuroblastoma
`
`Correspondence
`L. Chesler, Paediatric Solid Tumour Biology
`and Therapeutics Team, Division of Clinical
`Studies and Cancer Therapeutics Division,
`The Institute of Cancer Research, 15
`Cotswold Road, Sutton, Surrey SM2 5NG,
`UK
`Tel: +44 0208 722 4176
`E-mail: louis.chesler@icr.ac.uk
`
`†Joint first authors
`
`(Received 16 December 2016, revised 24
`March 2017, accepted 11 April 2017,
`available online 31 May 2017)
`
`doi:10.1002/1878-0261.12069
`
`1. Introduction
`
`The rapid development of targeted therapeutics against
`anaplastic
`lymphoma kinase
`(ALK) has already
`resulted in significant changes to the up-front treat-
`ment of patients with ALK-rearranged non-small-
`cell lung cancer (NSCLC) (Camidge et al., 2012), and
`a current aim is to bring these personalized therapies
`to the benefit of childhood cancer patients, including
`those with neuroblastomas that harbor point muta-
`tions of ALK (Chen et al., 2008; George et al., 2008;
`Janoueix-Lerosey et al., 2008; Mosse et al., 2008). The
`
`broad range of ALK mutations found either as a sec-
`ondary resistance mechanism to ALK inhibition in
`NSCLC or as a primary resistance mechanism in neu-
`roblastoma necessitates thorough interrogation of the
`ability of individual compounds to inhibit ALK phos-
`phorylation and subsequent survival signaling down-
`stream of ALK, enabling the rapid translation of the
`most promising compounds from the laboratory to
`clinical trials (Bresler et al., 2011, 2014). To achieve
`this, highly relevant preclinical models should be cou-
`pled with accurate methods to report pharmacody-
`namic responses.
`
`Abbreviations
`ALK, anaplastic lymphoma kinase; MSD
`

`, Meso Scale Discovery.
`
`996
`
`Molecular Oncology 11 (2017) 996–1006 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
`This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
`
`distribution and reproduction in any medium, provided the original work is properly cited.
`
`Lassen - Exhibit 1061, p. 1
`
`

`

`E. R. Tucker et al.
`
`Immunoassays to quantitate ALK
`
`We have therefore developed sensitive immunoassays
`to detect and quantitate the expression of total ALK
`protein and phosphorylated forms of ALK using the

`) platform. This format
`mesoscale technology (MSD
`allows for the development of assays that are appropri-

`ate for both in vitro and in vivo studies, and MSD
`assays are already routinely incorporated into clinical
`studies in order to measure pharmacodynamic end
`points (Basu et al., 2015). We sought to validate our
`ALK immunoassays using both neuroblastoma cell
`lines and tumor tissue from the Th-ALKF1174L/MYCN
`transgenic model, which has previously demonstrated
`the inadequacy of the first-generation ALK inhibitor,
`crizotinib,
`to elicit
`therapeutic responses
`in ALK
`F1174L-driven neuroblastomas (Berry et al., 2012).
`Our results demonstrate the successful application of

`immunoassays to measure ALK and phospho-
`MSD
`rylated ALK as pharmacodynamic biomarkers follow-
`ing treatment with small-molecule ALK inhibitors in
`both in vitro and ex vivo tissues. We show that in
`addition to autophosphorylation of ALK at Y1278
`and Y1604, following the fate of phosphorylated ALK
`at Y1586 also provides a marker of active ALK levels.
`
`2. Materials and methods
`
`2.1. Cell lines
`
`Neuroblastoma cell lines and HeLa cells were obtained
`from the American Type Culture Collection, CLB-GA
`was a gift from V. Combaret (Lyon), and these were
`shown to be mycoplasma-free using a PCR-based assay
`(Minerva Biolabs, Berlin, Germany). The Ba/F3 ALK
`F1174L cells were a gift from R. George (Boston, USA)
`and were transduced as described previously (George
`et al., 2008). Cells were cultured in RPMI 1640 media
`supplemented with 2 mM glutamine (Gibco, Thermo
`Fisher Scientific, Waltham, MA, USA), 1 9 MEM
`nonessential amino acids, and 10% FBS (Gibco) and
`grown at 37 °C with 5% CO2 in a humidified incubator.
`
`2.2. Drug treatments
`Cell lines were treated at 50–70% confluency at the
`indicated drug concentrations or with DMSO at a con-
`centration that matched the greatest DMSO for the drug-
`treated cells. Crizotinib and ceritinib were purchased
`from Shanghai Haoyuan Chemexpress Company.
`
`2.3. GI50 determination
`
`In order to calculate the half maximal growth inhibi-
`tory concentration (GI50) of individual compounds,
`
`neuroblastoma tumor cells were seeded into 96-well
`plates in a total volume of 100 lL and allowed to
`attach overnight. Compound (dissolved in DMSO)
`was added to wells in six replicates of 100 lL, across a
`concentration gradient including a DMSO-only con-
`trol, the next day. The cells were exposed to drug for
`72 h. Thereafter, the cell number in treated versus con-
`trol wells was estimated after cell fixation with 10%
`trichloroacetic acid and staining with sulforhodamine
`B in 1% acetic acid. The GI50 was calculated as the
`drug concentration that inhibits cell growth by 50%
`compared with control growth, according to nonlinear
`regression analysis, using GRAPHPAD PRISM (La Jolla,
`CA, USA).
`
`2.4. Preparation of protein lysates
`
`Cell lines were harvesting by scraping, spun at 500 g
`for 5 min, and washed once in phosphate-buffered sal-
`ine, and the cell pellets were resuspended in CHAPS
`lysis buffer [50 mM Tris/HCl pH 8.0, 1 mM EDTA,
`150 mM NaCl, 1% CHAPS, 0.2 mM PMSF, 1 : 50
`Phosphatase Inhibitor Cocktail 2 and 3 (Sigma-Aldrich,
`St. Louis, MO, USA), 1 : 100 Protease Inhibitor Cock-
`tail
`(Sigma-Aldrich)]. Frozen tissue
`samples were
`homogenized in CHAPS lysis buffer prepared as for cell
`lysates. After incubation for 30 min on ice, lysates were
`spun at 16 000 g for 15 min and the supernatant was
`collected. Protein concentrations were determined using
`BCA protein assay (Thermo Fisher Scientific) by com-
`parison with bovine serine albumin standard.
`
`2.5. ALK Meso Scale Discovery
`

`
`immunoassays
`
`Multiarray 96-well plates (Meso Scale Discovery) were
`coated overnight at 4 °C with 0.5 lg mL
`1 mouse
`total ALK antibody (Clone 31F12; Cell Signaling
`Technology Inc., Danvers, MA, USA) diluted in
`50 mM carbonate buffer. Plates were washed 5 9 in
`wash buffer (0.1% Tween 20 in Tris-buffered saline)
`and incubated for 1 h with blocking buffer (5% BSA
`in wash buffer). After washing, samples were added
`lysates being diluted to 20 lg per well
`with cell
`(in vitro) or 30 lg per well (in vivo) in 1 9 Tris Lysis
`Buffer (Meso Scale Discovery) or recombinant ALK
`protein (Thermo Fisher Scientific) diluted in phos-
`phate-buffered saline and incubated overnight at 4 °C.
`After washing, the plates were then incubated for 1 h
`with the appropriate antibody (0.4 lg mL
`1
`total
`ALK D5F3, 0.2 lg mL
`1 pY1278 ALK D59G10,
`1 pY1586 ALK 3B4, 0.2 lg mL
`0.4 lg mL
`1 pY1604
`ALK D96H9, or 0.2 lg mL
`1 phospho-tyrosine P-
`Tyr-1000,
`all
`purchased
`from Cell
`Signaling
`
`Molecular Oncology 11 (2017) 996–1006 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
`
`997
`
`Lassen - Exhibit 1061, p. 2
`
`

`

`Immunoassays to quantitate ALK
`
`E. R. Tucker et al.
`
`Technology Inc.), washed, and incubated for a further
`1 h with 0.5 lg mL
`1 anti-rabbit SULFO-tag anti-
`body. The plates were washed, 2 9 Read Buffer T
`(Meso Scale Discovery) was added to wells, and elec-
`trochemiluminescence counts were made using a MSD
`SECTOR Imager 6000.
`
`2.6. Immunoblotting
`Western blotting of 20 lg of denatured lysates was
`carried out using precast 4–12% Bis/Tris gels in 1 9
`MOPS running buffer [Thermo Fisher Scientific (Invi-
`trogen)]. A prestained molecular weight marker was
`loaded alongside the experimental samples (Invitro-
`gen). The gels were transferred to PVDF membranes
`at 30 V for 3 h, or at 0.05 mA overnight. The mem-
`branes were blocked for 1 h in 5% (w/v) nonfat dry
`milk in Tris-buffered saline with 0.1% Tween 20
`(TBST), and then incubated with primary antibody
`overnight at 4 °C in 2.5% milk TBST (ALK, pY1278
`ALK, pY1604 ALK, pY1586 ALK (all equivalent to

`immunoassay), ERK1/2,
`the
`respective MSD
`pERK1/2, Akt, pAkt, GAPDH, all from Cell Signal-
`ing Technology Inc.). Membranes were incubated with
`the appropriate horseradish peroxidase-linked sec-
`ondary antibody and proteins were visualized using
`electrochemical luminescence (ECL plus) [GE Health-
`care Life Sciences (Amersham Biosciences), Buckin-
`ghamshire, UK] detection system on a LAS-3000
`Imaging System [GE Healthcare Life Sciences (Fuji-
`film), Buckinghamshire, UK]. Quantification of blots
`was performed by densitometry using IMAGEJ software
`analysis (Schneider et al., 2012).
`
`2.7. Immunoprecipitation
`
`Cell lysates were subjected to preclearing before direct
`incubation with the antibody of interest (ALK; IgG)
`for an hour at 4 °C. Protein G beads were added to
`the lysate and incubated overnight at 4 °C. The next
`day, the samples were spun down for 30 s at 4 °C and
`the supernatant was discarded. The bead pellet was
`washed five times with lysis buffer, before denaturing
`by heating to 95 °C for 5 min in SDS sample buffer.
`
`2.8. Mouse models
`
`All experiments, including the breeding of transgenic
`animals, were performed in accordance with the local
`ethical review panel, the UK Home Office Animals
`(Scientific procedures) Act 1986, the ARRIVE (Animal
`Research: Reporting of In Vivo Experiments) guideli-
`(Kilkenny et al., 2010) and the UK NCRI
`nes
`
`(Workman et al., 2010). Th-ALKF1174L/
`guideline
`MYCN tumor-bearing animals were enrolled into ther-
`apeutic trials when their abdominal tumors reached
`5 mm in diameter according to palpation. Volumetric
`MRI was performed as previously described (Jamin
`et al., 2013), with each animal undergoing imaging on
`day 0 and day 7. The tumor volume at each time point
`was then calculated. For in vivo oral dosing on days
`1–7, crizotinib was dissolved in sterile water with 10%
`Tween 20. Ceritinib was dissolved in 0.5% methylcel-
`lulose, 0.5% Tween 80 with sterile water. Two hours
`following the final dose of either compound, tumor tis-
`sue was excised and snap-frozen prior to analysis.
`
`3. Results
`
`3.1. Detection of recombinant ALK (rALK) protein
`with immunoassays

`
`platform, we optimized immunoas-
`Using the MSD
`says to detect phosphorylated or total ALK protein.
`Confirmation of the ability of the assays to detect
`ALK or phosphorylated ALK species was sought
`through the use of a kinase active recombinant ALK
`(rALK) protein (Fig. 1). Using a titrating amount of
`rALK, we found that pan-pY ALK, pY1278 ALK,
`pY1586 ALK, pY1604 ALK, and total ALK were
`detected in a linear fashion in each assay (Fig. 1A).
`The reproducibility of the assays to detect rALK was
`assessed both within a single experiment (Fig. 1B) and
`across
`at
`least
`three
`independent
`experiments
`(Fig. 1C). In all cases, the intra-assay percentage coef-
`ficient of variation for pY1278, pY1604, and total
`ALK was less than 2.4%, 6.2%, and 6.2%, respec-
`tively. In four of five samples for the pY assay and the
`pY1586 assay, the coefficient of variation was less than
`2.5% and 5.4%, respectively. The interassay variability
`was less than 30% in all assays, indicating high repro-
`ducibility of the assay signals.
`
`3.2. Immunoassays quantitate ALK and
`phosphorylated ALK forms in neuroblastoma cell
`lines
`
`Gain-of-function mutations of ALK, which lead to
`constitutive ALK phosphorylation, are known to con-
`tribute to the aggressive nature of pediatric neuroblas-
`toma tumors, and therefore, the detection of ALK
`activity in available neuroblastoma cell
`lines is of
`increasing importance. We employed a panel of these
`cell lines harboring either one of the two most frequent
`ALK mutations (F1174L or R1275Q), or wild-type
`ALK, and assessed the total and phosphorylated
`
`998
`
`Molecular Oncology 11 (2017) 996–1006 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
`
`Lassen - Exhibit 1061, p. 3
`
`

`

`E. R. Tucker et al.
`
`Immunoassays to quantitate ALK
`
`pALK
`
`pY1278 ALK
`pY1586 ALK
`pY1604 ALK
`
`R 2 = 0.9187
`R 2 = 0.9296
`
`R 2 = 0.9581
`
`2.5
`
`2.0
`
`1.5
`
`1.0
`
`0.5
`
`0.0
`
`MSD ECL counts (×105)
`
`pY ALK
`
`R 2 = 0.9634
`
`0
`
`5
`
`20
`15
`10
`rALK (pg·µL–1)
`
`25
`
`0
`
`5
`
`20
`15
`10
`rALK (pg·µL–1)
`
`25
`
`7.0
`
`6.0
`
`5.0
`
`4.0
`
`3.0
`
`2.0
`
`1.0
`
`0.0
`
`MSD ECL counts (×105)
`
`Total ALK
`
`R 2 = 0.9562
`
`0
`
`50
`
`150
`100
`rALK (pg·µL–1)
`
`200
`
`Interassay variation
`
`pY
`
`pY1278
`
`pY1586
`
`pY1604
`
`Total ALK
`
`30
`
`25
`
`20
`
`15
`
`10
`
`C
`
`% CV
`
`05
`
`[rALK]
`
`Intra-assay variation
`
`pY
`
`pY1278
`
`pY1586
`
`pY1604
`
`Total ALK
`
`10.0
`9.0
`8.0
`7.0
`6.0
`5.0
`4.0
`3.0
`2.0
`1.0
`0.0
`
`A
`
`MSD ECL counts (×105)
`
`30
`
`25
`
`20
`
`15
`
`10
`
`B
`
`% CV
`
`05
`
`[rALK]
`
`Fig. 1. Immunoassays to quantitate phosphorylated and total ALK protein. (A) Titration of recombinant ALK protein (rALK) in MSD
`assays
`to quantify pan-phospho-tyrosine ALK, phospho-Y1278 ALK, phospho-Y1586 ALK, phospho-Y1604 ALK, and total ALK protein levels.
`Mean  SD from ≥ 3 independent
`repeats. R-squared values for
`linear
`regression from each of
`the assays are indicated. Assay

`assay with increasing
`intra-assay variability calculated across triplicate wells of each ALK MSD
`reproducibility was assessed by (B)
`concentrations of recombinant ALK protein (same as A) and (C) interassay variability calculated across from ≥ 3 independent repeats using
`increasing concentrations of recombinant ALK protein (same as A) and is presented as percentage coefficient of variation (CV).
`

`
`abundance of ALK by immunoblotting, in addition to
`pathways downstream of ALK (Fig. 2A). When com-
`pared to the Ba/F3-transduced cell
`lysates,
`it was
`apparent that detection and therefore quantification of
`phosphorylated ALK is challenging in the neuroblas-
`toma cell panel by western blotting as bands were only
`clearly visible for pY1278 and pY1586 ALK in CLB-
`GA and LAN-5 lysates. Phosphorylated Akt and
`phosphorylated ERK 1/2 signals were detected more
`strongly in CLB-GA and LAN-5 again, as well as in
`three of the four ALK F1174L cell
`lines, excluding
`Kelly cells. However, analyzing the same cell lysates in
`the ALK immunoassays we developed showed detect-
`able levels of pY1278, pY1586, pY1604, and total
`ALK in all the neuroblastoma cell lines tested, whereas
`no signals were obtained for HeLa cell lysate in any of
`the ALK assays consistent with the lack of ALK
`expression (Fig. 2B). When the levels of phosphory-
`lated ALK in the neuroblastoma cell lines were nor-
`malized to total ALK signals from the immunoassays
`and compared with densitometry of the immunoblots,
`there was a positive correlation that was statistically
`significant for the total ALK and pY1278 and pY1586
`
`ALK assays, and although not significant, a positive
`trend between densitometry and immunoassay for the
`detection of pY1604 ALK was seen (Fig. 2C). Further-
`more, upon immunoprecipitation of ALK and detec-
`tion of pan-pY from the same lysates (Fig. 2D), there
`was a stronger pY signal obtained for the two cell
`lines harboring the R1275Q ALK mutation (CLB-GA
`and LAN-5). This finding is consistent with CLB-GA
`and LAN-5 cell lysates giving the highest signals out
`of the cell
`line panel
`in the pY1278, pY1586, and
`pY1604 ALK assays (Fig. 2B) and the pY ALK

`assay (Fig. 2E). Together, these data indicate
`MSD
`that the ALK immunoassays can be used to character-
`ize basal levels of ALK activity in neuroblastoma cells
`in a more quantitative manner and with greater sensi-
`tivity than immunoblotting.
`
`3.3. ALK immunoassays quantify the dose- and
`time-dependent response of neuroblastoma cell
`lines to therapeutic ALK inhibition
`
`the phospho-ALK
`To further assess the ability of
`MSD assays to measure changes in ALK activity, we
`
`Molecular Oncology 11 (2017) 996–1006 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
`
`999
`
`Lassen - Exhibit 1061, p. 4
`
`

`

`Immunoassays to quantitate ALK
`
`E. R. Tucker et al.
`
`made use of two clinical small-molecule ALK inhibi-
`tors, crizotinib and ceritinib. Crizotinib was less suc-
`cessful against ALK F1174L neuroblastomas in clinical
`trial, but showed efficacy in the treatment for ALK
`
`R1275Q neuroblastomas (Mosse et al., 2013). Ceritinib
`is a second-generation ALK inhibitor, currently being
`evaluated in pediatric clinical studies. We used two
`neuroblastoma cell
`lines to compare crizotinib and
`
`6
`
`4
`
`2
`
`r = 0.9936
`P < 0.0001***
`
`0
`0.00
`
`012345
`
`0.15
`0.10
`0.05
`Immunoblot quantitation
`(pY1278 ALK/tALK)/GAPDH
`
`0.20
`
`r = 0.7254
`P = ns
`
`0.00
`
`0.06
`0.04
`0.02
`Immunoblot quantitation
`(pY1604 ALK/tALK)/GAPDH
`
`0.08
`
`Hela
`
`IMR-32
`
`LAN-5
`
`MSD ECL counts (×103)
`
`MSD ECL counts (×103)
`
`r = 0.9202
`P = 0.0033**
`
`0.0
`
`1.0
`0.5
`Immunoblot quantitation
`tALK/GAPDH
`
`1.5
`
`r = 0.9465
`P = 0.0012**
`
`0.0
`
`0.4
`0.3
`0.2
`0.1
`Immunoblot quantitation
`(pY1586 ALK/tALK)/GAPDH
`
`0.5
`
`8
`
`6
`
`4
`
`2
`
`0
`
`10
`
`02468
`
`D
`
`C
`
`MSD ECL counts (×105)
`
`MSD ECL counts (×103)
`
`Hela
`
`IMR-32
`
`LAN-5
`
`CLB-GA
`
`Kelly
`
`SK-N-SH
`
`LAN-1
`
`SH-SY5Y
`
`Ba/F3 ALKF1174L
`
`A
`
` pY1278 ALK
`
`pY1586 ALK
`
`pY1604 ALK
`
`Total ALK
`
`pS473 Akt
`
`Total Akt
`
`pERK 1/2
`
`ERK 1/2
`
`GAPDH
`
`B
`
`12.0
`
`10.0
`
`pY1278 ALK
`pY1586 ALK
`pY1604 ALK
`
`CLB-GA
`
`Kelly
`
`SK-N-SH
`
`LAN-1
`
`SH-SY5Y
`
`Ba/F3 ALKF1174L
`
`pY ALK
`
`HeLa
`
`IMR-32
`
`LAN-5
`
`CLB-GA
`
`Kelly
`
`SK-N-SH
`
`LAN-1
`
`SH-SY5Y
`
`Total ALK
`
`IP ALK
`
`IP pY
`
`E
`
`4.0
`
`3.0
`
`2.0
`
`1.0
`
`0.0
`
`MSD ECL counts (x104)
`
`Hela
`
`IMR-32
`
`LAN-5
`
`CLB-GA
`
`Kelly
`
`SK-N-SH
`
`LAN-1
`
`SH-SY5Y
`
`Total ALK
`
`HeLa
`
`IMR-32
`
`LAN-5
`
`CLB-GA
`
`Kelly
`
`SK-N-SH
`
`LAN-1
`
`SH-SY5Y
`
`8.0
`
`6.0
`
`4.0
`
`2.0
`
`0.0
`
`MSD ECL counts (x103)
`
`8.0
`7.0
`6.0
`5.0
`4.0
`3.0
`2.0
`1.0
`0.0
`
`MSD ECL counts (x105)
`
`ALK status:
`
`F1174L
`
`R1275Q
`
`WT
`
`-
`
`ALK status:
`
`F1174L
`
`R1275Q
`
`WT
`
`-
`
`1000
`
`Molecular Oncology 11 (2017) 996–1006 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
`
`Lassen - Exhibit 1061, p. 5
`
`

`

`E. R. Tucker et al.
`
`Immunoassays to quantitate ALK
`
`in a dose-dependent and time-
`ceritinib treatment
`dependent manner using the total ALK, pY ALK,
`pY1278, pY1604, and pY1586 ALK immunoassays
`(Fig. 3). The drug concentrations were decided using
`the GI50 values for each compound (Table 1). Kelly
`cells
`(ALK F1174L) demonstrated a similar dose
`response to both drugs (Fig. 3A) with inhibition of
`ALK phosphorylation at sub-GI50 concentrations, and
`this similarity was reflected in the accompanying immu-
`noblot
`(pY1604 and pY1278 immunoblots did not
`detect bands and are therefore not included). CLB-GA
`cells (ALK R1275Q) (Fig. 3B) were more sensitive to
`treatment with ceritinib than with crizotinib, with over
`50% inhibition of phosphorylation seen with all phos-
`pho-ALK assays at 10 nM ceritinib. This result is also
`seen in the accompanying immunoblot (pY1604 immu-
`noblot did not detect bands and is therefore not
`included) (Fig. 3B). In both cell lines, loss in pY1586
`ALK signal follows the pattern of decreasing pY ALK,
`pY1604 ALK, and pY1278 ALK (CLB-GA only) with
`ALK inhibition and a reduction in band intensity in
`the accompanying immunoblots for pY1278 ALK.
`Although ALK phosphorylation was inhibited at sub-
`GI50 concentrations of crizotinib or ceritinib, signaling
`pathways downstream of ALK, such as AKT and
`ERK1/2, were not inhibited until higher concentrations
`at 3-hour treatment (immunoblots in Fig. 3A,B). The
`results of the dose–response experiments led to the
`choice of drug concentrations to be used in the subse-
`quent time course experiments, as the dose that led to a
`percentage of DMSO treated at near 20% phosphory-
`lated ALK.
`There was a rapid decrease in the phosphorylated/to-
`tal ALK ratio (P/T ratio)
`in Kelly cells (Fig. 3C)
`(graphed as percentage of zero-hour control sample) fol-
`lowing the treatment of the cells with either crizotinib or
`ceritinib. This effect was sustained for 24 h and is
`reflected in the accompanying immunoblots of the same
`lysates, where sustained inhibition of phosphorylated
`ERK1/2, a downstream effector of ALK, is also appar-
`ent
`following the treatment with either compound.
`Subtle inhibition of phosphorylation of Akt at S473 was
`also evident following the treatment of Kelly cells with
`
`crizotinib or ceritinib. Treatment of CLB-GA cells
`(Fig. 3D) with either crizotinib or ceritinib also resulted
`in a rapid reduction in P/T ALK ratio from 10-min
`treatment, an effect that was also sustained for the entire
`24-h time course. At 50 nM, there was some evidence
`that the downstream effectors of ALK were differen-
`tially affected following the treatment with either com-
`pound. Dephosphorylation of Akt at S473 occurred
`more rapidly after treatment of the cells with crizotinib;
`however, although treatment with either compound
`gave rise to a loss of ERK1/2 phosphorylation quickly,
`this effect was transient and not sustained for the dura-
`tion of the experiment. Together, our results indicate
`that a sustained dephosphorylation of ALK at multiple
`phosphorylation sites by both crizotinib and ceritinib
`can be detected quantitatively by immunoassay in neu-
`roblastoma cell lines with ALK mutations at F1174L or
`R1275Q.
`
`3.4. Treatment of Th-ALKF1174L/MYCN tumor-
`bearing animals demonstrates increased efficacy
`of ceritinib over crizotinib and a greater
`pharmacodynamic response
`
`Finally, we tested frozen tissue specimens from Th-
`ALKF1174L/MYCN animals
`(in which spontaneous
`tumors arise, driven by coexpression of the human
`ALKF1174L and human MYCN transgenes), which had
`been treated with either crizotinib or ceritinib for
`7 days. Treatment of animals with ceritinib (100 mg kg
`1
`per day) results in delayed growth or tumor regression
`[established using noninvasive MRI volumetric measure-
`ments (Fig. 4B depicts representative images)], compared
`to delayed growth only following the treatment with
`crizotinib (100 mg kg
`1 per day) (Fig. 4A). The quanti-
`tation of pY1586 ALK and total ALK by immunoassay
`is
`shown next
`to the corresponding immunoblots
`(Fig. 4C,D). The ratio of pY1586 to total ALK revealed
`a mean decrease to 0.34 following crizotinib treatment
`versus 0.17 following ceritinib treatment (each normal-
`ized to the mean of their respective vehicle controls)
`(Fig. 4E), indicating a larger pharmacodynamic effect
`with ceritinib, consistent with the tumor volume data
`
`Fig. 2. Basal ALK activity in neuroblastoma cell lines. (A) Immunoblots of lysates from neuroblastoma cell line panel, including lysate from
`Ba/F3 ALK F1174L as a positive control for ALK expression and lysate from Hela cells as negative control for ALK expression. Arrows
`indicate ALK band of interest at 220 kDa. (B) Quantitation of phospho-Y1278 ALK, phospho-Y1586 ALK, phospho-Y1604 ALK, and total ALK
`protein levels in a cell line panel using immunoassays. Mean  SD from ≥ 3 biological repeats. (C) Correlation of MSD

`ECL counts with
`quantitation of total ALK (tALK) (P = 0.0033**) and phospho-ALK (pY1278 ALK P = < 0.0001***; pY1586 ALK P = 0.0012**; pY1604 ALK
`P = ns (not significant)) immunoblots for neuroblastoma cell lysates. r values for Pearson’s rank correlation of each graph are indicated. (D)
`Immunoprecipitation of total ALK from the same neuroblastoma cell line panel lysates (as in (A)), to allow the assessment of pan-phospho-
`line panel by immunoassay. Mean  SD from ≥ 3 biological
`tyrosine ALK status. (E) Quantitation of pan-phospho-tyrosine ALK, in a cell
`repeats.
`
`Molecular Oncology 11 (2017) 996–1006 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
`
`1001
`
`Lassen - Exhibit 1061, p. 6
`
`

`

`E. R. Tucker et al.
`
`Total ALK
`pY ALK
`pY1278 ALK
`pY1586 ALK
`pY1604 ALK
`
`200
`180
`160
`140
`120
`100
`80
`60
`40
`20
`
`Ceritinib (nM)
`
`160
`140
`120
`100
`80
`60
`40
`20
`0
`–20
`
`Percentage of DMSO treated
`
`200
`180
`160
`140
`120
`100
`80
`60
`40
`20
`
`Crizotinib (nM)
`
`CLB-GA
`
`Crizotinib
`
`Ceritinib
`
`nM
`
`0 5 20 50 200 0 5 20 50 200
`
`Immunoassays to quantitate ALK
`
`B
`
`160
`140
`120
`100
`80
`60
`40
`20
`0
`–20
`
`Percentage of DMSO treated
`
`Total ALK
`pY ALK
`pY1586 ALK
`pY1604 ALK
`
`600
`550
`500
`450
`400
`350
`300
`250
`200
`150
`100
`50
`
`Ceritinib (nM)
`
`160
`140
`120
`100
`80
`60
`40
`20
`0
`–20
`
`Percentage of DMSO treated
`
`Kelly
`
`600
`550
`500
`450
`400
`350
`300
`250
`200
`150
`100
`50
`
`Crizotinib (nM)
`
`A
`
`160
`140
`120
`100
`80
`60
`40
`20
`0
`–20
`
`Percentage of DMSO treated
`
`Crizotinib
`
`Ceritinib
`
`nM
`
`0 20 50 200 500 0 20 50 200 500
`
`pY1278 ALK
`
`pY1586 ALK
`
`Total ALK
`
`pS473 Akt
`
`Total Akt
`
`pERK 1/2
`
`ERK 1/2
`
`GAPDH
`
`pY1278 ALK
`pY1586 ALK
`pY1604 ALK
`pY ALK
`
`24 h
`6 h
`3 h
`1 h
`10 min
`0 min
`24 h
`6 h
`3 h
`1 h
`10 min
`0 min
`24 h
`6 h
`3 h
`1 h
`10 min
`0 min
`24 h
`6 h
`3 h
`1 h
`10 min
`0 min
`24 h
`6 h
`3 h
`1 h
`10 min
`0 min
`24 h
`6 h
`3 h
`1 h
`10 min
`0 min
`24 h
`6 h
`3 h
`1 h
`10 min
`0 min
`24 h
`6 h
`3 h
`1 h
`10 min
`0 min
`
`D
`
`100
`
`80
`
`60
`
`40
`
`20
`
`0
`
`P/T ratio (% 0 h control)
`
`Crizotinib
`
`CLB-GA
`
`Ceritinib
`
`50 nM crizotinib
`0 10 min 1 h 3 h 6 h 24 h
`
`50 nM ceritinib
`
`0 10 min 1 h 3 h 6 h 24 h
`
`Time
`
`pY1278 ALK
`
`pY1586 ALK
`
`Total ALK
`
`pS473 Akt
`
`Total Akt
`
`pERK 1/2
`
`ERK 1/2
`
`GAPDH
`
`pY1586 ALK
`
`Total ALK
`
`pS473 Akt
`
`Total Akt
`
`pERK 1/2
`
`ERK 1/2
`
`GAPDH
`
`pY1586 ALK
`pY1604 ALK
`pY ALK
`
`24 h
`6 h
`3 h
`1 h
`10 min
`0 min
`24 h
`6 h
`3 h
`1 h
`10 min
`0 min
`24 h
`6 h
`3 h
`1 h
`10 min
`0 min
`24 h
`6 h
`3 h
`1 h
`10 min
`0 min
`24 h
`6 h
`3 h
`1 h
`10 min
`0 min
`24 h
`6 h
`3 h
`1 h
`10 min
`0 min
`
`Crizotinib
`
`Ceritinib
`
`Kelly
`
`200 nM crizotinib
`
`200 nM ceritinib
`
`Time
`
`0 10 min 1 h 3 h 6 h 24 h
`
`0 10 min 1 h 3 h 6 h 24 h
`
`C
`
`100
`
`80
`
`60
`
`40
`
`20
`
`0
`
`P/T ratio (% 0 h control)
`
`pY1586 ALK
`
`Total ALK
`
`pS473 Akt
`
`Total Akt
`
`pERK 1/2
`
`ERK 1/2
`
`GAPDH
`
`1002
`
`Molecular Oncology 11 (2017) 996–1006 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
`
`Lassen - Exhibit 1061, p. 7
`
`

`

`E. R. Tucker et al.
`
`Immunoassays to quantitate ALK
`
`Fig. 3. Dose–response and time course comparison of ALK inhibition by crizotinib or ceritinib. Dose response in Kelly (A) and CLB-GA (B)

`neuroblastoma cells with 3-hour treatment of crizotinib or ceritinib. Phosphorylated and total ALK levels were quantified by MSD
`immunoassays, and mean  SD from three independent repeats are shown. Corresponding immunoblots of Kelly and CLB-GA cell lysates
`following the treatment with either crizotinib or ceritinib are shown below as indicated. Vertical dashed lines indicate GI50. Time course
`treatment of Kelly cells (C) with crizotinib or ceritinib (both 200 nM) and CLB-GA cells (D) with crizotinib or ceritinib (both 50 nM).

`immunoassays (three independent repeats), and the phosphorylated ALK/
`Phosphorylated and total ALK levels were quantified by MSD
`total ALK ratio as a % of untreated is plotted. Corresponding immunoblots of Kelly and CLB-GA cell lysates following the treatment with
`either crizotinib or ceritinib are shown below as indicated.
`
`(Fig. 4A). Our results suggest that these immunoassays
`are suitable for the quantification of ALK as a biomarker
`following the targeted therapy in vivo.
`
`4. Discussion
`
`In this report, we have validated immunoassays to
`detect ALK and phosphorylated ALK in vitro, success-
`fully applied them to an in vivo model of neuroblas-
`toma, and demonstrated a quantitative difference in
`on-target pharmacodynamic changes between a first-
`and second-generation ALK inhibitor.
`To date, the majority of studies investigating the
`mechanism of activation and phosphorylation of ALK
`utilize oncogenic ALK fusion proteins, such as NPM-
`ALK. Activation of full-length ALK has been shown to
`result in the phosphorylation of Y1278 alongside Y1282
`and Y1283, which lie in the Y’Ras’YY autophosphory-
`lation motif within the activation loop (Tartari et al.,
`2008). Y1604 is found at the C-terminal tail of the recep-
`tor and has been reported to be important for transfor-
`mation activity and docking of phospholipase Cy in
`studies on NPM-ALK. Subsequently, Y1604 and Y1586
`were together identified as tyrosine sites phosphorylated
`following ALK activation in a phosphoproteomics
`study of full-length ALK (Sattu et al., 2013), and the
`detection of dephosphorylation at Y1586 by our
`immunoassay, following the treatment with ALK inhi-
`bitors, confirms the role of this phosphorylation site in
`the constitutive activity of ALK.
`Our panel of neuroblastoma cell lines harbor either
`the ALK F1174L or the ALK R1275Q mutation or
`
`Table 1. 72-Hour GI50 of crizotinib or ceritinib in neuroblastoma cell
`lines (nM).
`
`Cell lines
`
`Crizotinib
`
`SH-SY5Y
`LAN-1
`SK-N-SH
`Kelly
`CLB-GA
`LAN-5
`IMR-32
`
`480.6  93.0
`236.6  9.8
`3059.5  272.2
`432.4  28.6
`167.6  48.3
`132.0  22.8
`511.7  29.1
`Mean  SD from three independent repeats.
`
`Ceritinib
`
`82.0  25.4
`46.8  36.3
`1311.5  252.4
`542.4  62.2
`43.4  7.3
`47.3  6.3
`1203.8  386.7
`
`express wild-type ALK only and therefore represent
`two of the three hotspots of ALK mutation sites in
`et al., 2014). Our
`neuroblastoma tumors
`(Bresler
`cross-comparison of
`immunoblots with the ALK
`immunoassays
`reveals
`strong
`correlation of
`the
`detection of total ALK and two of three ALK phos-
`phorylation sites (Fig. 2, Section 3.2.). The immuno-
`precipitation of ALK and detection of pY furthermore
`reflect the results from the pY ALK immunoassay.
`Measurement of phosphorylated ALK by immunoas-
`say has several advantages over western blotting such
`as greater quantitative power and higher-throughput

`platform we used also
`analysis of samples. The MSD
`provides
`superior
`sensitivity and a much greater
`dynamic range in which to detect changes in ALK
`activity.
`Interestingly, by analyzing a neuroblastoma cell line
`panel, we found that cells with the ALK R1275Q
`mutation had the strongest ALK phosphorylation sig-
`nals. R1275 accounts for 43% of ALK mutations in
`neuroblastoma, yet mutations at the F1174 locus (ac-
`counting for 30% of ALK mutations) are reported to
`have the strongest effect on nonphosphorylated ALK
`tyrosine kinase domain in vitro (Bresler et al., 2014). It
`is possible that ALK activity is different in a whole-
`cell environment and acclimatization to cell culture
`conditions alters the dominant cell signaling pathways
`and accounts for this discrepancy between purified
`mutated ALK tyrosine kinase domain experiments and
`our cell-based approaches. Furthermore, we show that
`dephosphorylation at the pY1586 site closely followed
`dephosphorylation at
`the pY1278
`and pY1604
`autophosphorylation sites upon ALK inhibition, and
`therefore, phosphorylation of ALK at any of these
`three
`sites
`could be used as pharmacodynamic
`biomarkers for ALK activity.
`Crizotinib and ceritinib are both under clinical evalu-
`ation for the treatment of ALK-positive neuroblastomas
`with genetic ALK alterations, and our immunoassays
`allow for a direct pharmacodynamic preclinical compar-
`ison of the two compounds (Mosse et al., 2013). The
`observation that ceritinib has a lower GI50 in CLB-GA
`than crizotinib is supported by the results of
`the
`immunoassay in these cells, where we see inhibition of
`
`Molecular Oncology 11 (2017) 996–1006 ª 2017 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
`
`1003
`
`Lassen - Exhibit 1061, p. 8
`
`

`

`Immunoassays to quantitate ALK
`
`E. R. Tucker et al.
`
`*P = 0.0254
`
`***P = 0.0008
`
`B
`CrizoƟnib
`vehicle
`
`CrizoƟnib
`
`CeriƟnib
`vehicle
`
`Ceritinib
`
`Day 0
`
`Day 7
`
`Vehicle
`
`Crizotinib
`
`Vehicle
`
`Ceritinib
`
`20
`
`15
`
`10
`
`5
`
`0
`
`D
`
`MSD ECL counts (x104)
`
`Total ALK
`
`GAPDH
`
`Vehicle
`
`Crizotinib
`
`Vehicle
`
`Ceritinib
`
`Vehicle
`
`Crizotinib
`
`Vehicle
`
`Ceritinib
`
`ns
`
`*P = 0.0256
`
`300
`
`200
`
`100
`
`0
`
`–100
`
`2500
`
`2000
`
`1500
`
`1000
`
`500
`
`0
`
`MSD ECL counts
`
`A
`
`% Volume change at day 7
`
`C
`
`pY1586 ALK
`
`GAPDH
`
`2.0
`
`1.5
`
`1.0
`
`0.5
`
`0.0
`
`P/T ratio
`
`Normalized
`
`E
`
`Vehicle Crizotinib Vehicle
`
`Ceritinib
`

`
`
`immunoassay quantitation of Th-ALKF1174L/MYCN tumors

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket